Skip to main content

Compare Stocks

Date Range: 

 ImmunovantAlectorREGENXBIOReplimune GroupAlloVir
SymbolNASDAQ:IMVTNASDAQ:ALECNASDAQ:RGNXNASDAQ:REPLNASDAQ:ALVR
Price Information
Current Price$15.50$17.00$36.14$35.05$24.00
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.31.61.51.5
Analysis Score3.53.53.43.53.5
Community Score3.72.42.72.43.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.81.71.70.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$44.93$34.40$62.50$56.00$49.25
% Upside from Price Target189.89% upside102.35% upside72.94% upside59.77% upside105.21% upside
Trade Information
Market Cap$1.52 billion$1.36 billion$1.54 billion$1.63 billion$1.56 billion
BetaN/A1.081.282.63N/A
Average Volume1,290,661623,224431,114377,760338,141
Sales & Book Value
Annual RevenueN/A$21.22 million$35.23 millionN/AN/A
Price / SalesN/A63.9043.61N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.45 per share$2.83 per share$12.23 per share$5.01 per shareN/A
Price / BookN/A6.012.96N/AN/A
Profitability
Net Income$-66,390,000.00$-105,390,000.00$-94,730,000.00$-52,630,000.00N/A
EPS($1.54)($1.71)($3.26)($1.54)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-757.78%-63.13%N/AN/A
Return on Equity (ROE)-34.80%-53.86%-21.73%-30.23%N/A
Return on Assets (ROA)-32.38%-31.44%-18.74%-24.66%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.13%N/A
Current Ratio35.15%6.61%6.08%19.47%28.40%
Quick Ratio35.15%6.61%6.08%19.47%28.40%
Ownership Information
Institutional Ownership Percentage40.21%61.50%75.23%55.79%32.07%
Insider Ownership Percentage0.24%13.90%14.10%50.90%1.00%
Miscellaneous
Employees4217130612253
Shares Outstanding97.97 million79.77 million42.51 million46.49 million65.11 million
Next Earnings Date7/5/2021 (Estimated)8/10/2021 (Estimated)8/5/2021 (Estimated)6/2/2021 (Estimated)9/1/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
SVB Leerink Raises AlloVir (NASDAQ:ALVR) Price Target to $42.00SVB Leerink Raises AlloVir (NASDAQ:ALVR) Price Target to $42.00
americanbankingnews.com - May 12 at 11:02 AM
SVB Leerink Increases AlloVir (NASDAQ:ALVR) Price Target to $42.00SVB Leerink Increases AlloVir (NASDAQ:ALVR) Price Target to $42.00
marketbeat.com - May 12 at 8:42 AM
AlloVir (NASDAQ:ALVR) Trading Down 7.6% Following Insider SellingAlloVir (NASDAQ:ALVR) Trading Down 7.6% Following Insider Selling
americanbankingnews.com - May 11 at 10:19 AM
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings - BenzingaThe Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings - Benzinga
benzinga.com - May 11 at 8:03 AM
AlloVir, Inc. (NASDAQ:ALVR) Insider Sells $3,412,500.00 in StockAlloVir, Inc. (NASDAQ:ALVR) Insider Sells $3,412,500.00 in Stock
americanbankingnews.com - May 10 at 5:54 PM
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth - NasdaqWe Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth - Nasdaq
nasdaq.com - May 8 at 12:55 PM
AlloVir (NASDAQ:ALVR) Releases  Earnings Results, Misses Expectations By $0.10 EPSAlloVir (NASDAQ:ALVR) Releases Earnings Results, Misses Expectations By $0.10 EPS
americanbankingnews.com - May 7 at 5:36 PM
Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (GBT), AlloVir (ALVR) and Ortho Clinical Diagnostics Holdings (OCDX) - Smarter AnalystAnalysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (GBT), AlloVir (ALVR) and Ortho Clinical Diagnostics Holdings (OCDX) - Smarter Analyst
smarteranalyst.com - May 6 at 4:16 PM
Form 8-K Allovir, Inc. For: May 06 - StreetInsider.comForm 8-K Allovir, Inc. For: May 06 - StreetInsider.com
streetinsider.com - May 6 at 4:16 PM
AlloVir Reports First Quarter 2021 Financial Results - BioSpaceAlloVir Reports First Quarter 2021 Financial Results - BioSpace
biospace.com - May 6 at 4:16 PM
AlloVir Reports First Quarter 2021 Financial ResultsAlloVir Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 4:16 PM
AlloVir (NASDAQ:ALVR) Given New $42.00 Price Target at SVB LeerinkAlloVir (NASDAQ:ALVR) Given New $42.00 Price Target at SVB Leerink
americanbankingnews.com - May 6 at 1:01 PM
ALLOVIR, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.comALLOVIR, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - May 6 at 11:16 AM
AlloVir Reports First Quarter 2021 Financial Results - Business WireAlloVir Reports First Quarter 2021 Financial Results - Business Wire
businesswire.com - May 6 at 11:16 AM
AlloVir (NASDAQ:ALVR)  Shares Down 5.7% AlloVir (NASDAQ:ALVR) Shares Down 5.7%
americanbankingnews.com - May 5 at 2:22 PM
Cytomegalovirus Infection Emerging Drugs to Boost Treatment - GlobeNewswireCytomegalovirus Infection Emerging Drugs to Boost Treatment - GlobeNewswire
globenewswire.com - May 4 at 9:49 AM
Cytomegalovirus Infection Emerging Drugs to Boost Treatment Prospects - StockhouseCytomegalovirus Infection Emerging Drugs to Boost Treatment Prospects - Stockhouse
stockhouse.com - May 3 at 11:56 PM
AlloVir (NASDAQ:ALVR) Trading Up 4.7%AlloVir (NASDAQ:ALVR) Trading Up 4.7%
americanbankingnews.com - April 29 at 4:59 PM
Is Allovir Inc (ALVR) Stock About to Get Hot Monday? - InvestorsObserverIs Allovir Inc (ALVR) Stock About to Get Hot Monday? - InvestorsObserver
investorsobserver.com - April 26 at 3:45 PM
AlloVir (NASDAQ:ALVR) Price Target Raised to $50.00AlloVir (NASDAQ:ALVR) Price Target Raised to $50.00
americanbankingnews.com - April 26 at 9:32 AM
AlloVir: Targeting Infectious Diseases In Stem Cell Transplant Patients - Seeking AlphaAlloVir: Targeting Infectious Diseases In Stem Cell Transplant Patients - Seeking Alpha
seekingalpha.com - April 24 at 6:11 AM
AlloVir (NASDAQ:ALVR) Trading Down 3.7%AlloVir (NASDAQ:ALVR) Trading Down 3.7%
americanbankingnews.com - April 23 at 12:52 PM
Morgan Stanley Thinks AlloVir’s Stock is Going to Recover - Smarter AnalystMorgan Stanley Thinks AlloVir’s Stock is Going to Recover - Smarter Analyst
smarteranalyst.com - April 19 at 6:17 PM
Should You Buy Allovir Inc (ALVR) in Biotechnology Industry? - InvestorsObserverShould You Buy Allovir Inc (ALVR) in Biotechnology Industry? - InvestorsObserver
investorsobserver.com - April 12 at 2:06 PM
Analysts Say These 3 Perfect 10 Stocks Are Their Top Picks For 2021 - Investing.comAnalysts Say These 3 'Perfect 10' Stocks Are Their Top Picks For 2021 - Investing.com
investing.com - April 8 at 10:37 AM
Mission Bio Taps Thermo Fisher Scientific Veteran Yan Zhang as New CEO - BioSpaceMission Bio Taps Thermo Fisher Scientific Veteran Yan Zhang as New CEO - BioSpace
biospace.com - April 8 at 10:37 AM
DateCompanyBrokerageAction
5/10/2021ImmunovantHC WainwrightLower Price Target
2/16/2021ImmunovantStifel NicolausReiterated Rating
2/3/2021ImmunovantRaymond JamesLower Price Target
2/3/2021ImmunovantSVB LeerinkLower Price Target
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
11/12/2020ImmunovantChardan CapitalBoost Price Target
10/28/2020ImmunovantUBS GroupInitiated Coverage
10/12/2020ImmunovantGuggenheimInitiated Coverage
10/6/2020ImmunovantLifesci CapitalReiterated Rating
10/2/2020ImmunovantCSFBInitiated Coverage
4/26/2021AlectorMorgan StanleyBoost Price Target
1/15/2021AlectorBank of AmericaInitiated Coverage
11/11/2020AlectorSmith Barney CitigroupLower Price Target
7/29/2020AlectorBarclaysLower Price Target
4/28/2020AlectorThe Goldman Sachs GroupInitiated Coverage
3/5/2020AlectorCitigroupInitiated Coverage
12/16/2019AlectorCowenReiterated Rating
11/27/2019AlectorBTIG ResearchInitiated Coverage
1/20/2021REGENXBIORoyal Bank of CanadaBoost Price Target
11/11/2019REGENXBIOEvercore ISIReiterated Rating
11/6/2020Replimune GroupBMO Capital MarketsBoost Price Target
11/2/2020Replimune GroupJefferies Financial GroupInitiated Coverage
10/14/2020Replimune GroupRoth CapitalBoost Price Target
6/3/2020Replimune GroupWedbushReiterated Rating
2/11/2021AlloVirPiper SandlerBoost Price Target
8/24/2020AlloVirJPMorgan Chase & Co.Initiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.